RT Journal Article
SR Electronic
T1 Drivers of adaptive evolution during chronic SARS-CoV-2 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22270829
DO 10.1101/2022.02.17.22270829
A1 Sheri Harari
A1 Maayan Tahor
A1 Natalie Rutsinsky
A1 Suzy Meijer
A1 Danielle Miller
A1 Oryan Henig
A1 Ora Halutz
A1 Katia Levytskyi
A1 Ronen Ben-Ami
A1 Amos Adler
A1 Yael Paran
A1 Adi Stern
YR 2022
UL http://medrxiv.org/content/early/2022/02/28/2022.02.17.22270829.abstract
AB In some immunocompromised patients with chronic SARS-CoV-2 infection, dramatic adaptive evolution occurs, with substitutions reminiscent of those in variants of concern (VOCs). Here, we searched for drivers of VOC-like emergence by consolidating sequencing results from a set of twenty-seven chronic infections. Most substitutions in this set reflected lineage-defining VOC mutations, yet a subset of mutations associated with successful global transmission was absent from chronic infections. The emergence of these mutations might dictate when variants from chronic infections can dramatically spread onwards. Next, we tested the ability to predict antibody-evasion mutations from patient- and viral-specific features, and found that viral rebound is strongly associated with the emergence of antibody-evasion. We found evidence for dynamic polymorphic viral populations in most patients, suggesting that a compromised immune system selects for antibody-evasion in particular niches in a patient’s body. We suggest that a trade-off exists between antibody-evasion and transmissibility that potentially constrains VOC emergence, and that monitoring chronic infections may be a means to predict future VOCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by an ERC starting grant 852223 (RNAVirFitness), and by an Israeli Science Foundation grant 3963/19. This study was supported in part by a fellowship to SH from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the TASMC Helsinki committee (approval No. 1042-20-TLV), and by the Tel Aviv University IRB (approval number 0004435-1), with an exemption from informed consent .I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll consensus sequences for the patients sequenced herein were deposited in GISAID, and raw sequencing reads were uploaded to the NCBI Sequence Read Archive under submission number PRJNA803960. Full details are available in the manuscript supplementary material.